Biomarker & Intervention Discovery
Lupus Nephritis
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs2.70MWHO GHE 2021 · all ages
Global DALYs43.51MWHO GHE 2021 · worldwide
US mortality104.2K deaths/yrWHO GHE 2021
Global mortality1.39M deaths/yrWHO GHE 2021 · worldwide
NIH funding$148MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionSpontaneous remission essentially zero in class III/IV LN; progression to ESRD in 10-20% at 10 years on standard…
Best-intervention remissionVoclosporin + MMF + low-dose OCS: 40.8% complete renal response at 52 weeks (AURORA 1); belimumab + SOC: 43% primary…
Gap sizeModerate — better outcomes available with triple therapy but access and racial disparities limit implementation
Primary barrieraccess/practice
Full remission profile →
Remission & chronicity
Spontaneous remission
Spontaneous remission essentially zero in class III/IV LN; progression to ESRD in 10-20% at 10 years on standard therapy; renal flares in 30-50% of patients achieving initial response
Best-intervention remission
Voclosporin + MMF + low-dose OCS: 40.8% complete renal response at 52 weeks (AURORA 1); belimumab + SOC: 43% primary efficacy renal response (BLISS-LN); obinutuzumab + MMF + SOC: superior histological response vs rituximab (NOBILITY)
Gap size
Moderate — better outcomes available with triple therapy but access and racial disparities limit implementation
Primary barrier
access/practice
Black and Hispanic patients have significantly worse LN outcomes and are underrepresented in landmark trials; voclosporin and belimumab add significant cost; cyclophosphamide still used in some settings where MMF is equally effective in non-Black patients (Euro-Lupus low-dose equivalent); racial disparities in specialist access
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Lupus Nephritis” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."